Literature DB >> 27490192

Transplacental passage of clindamycin from mother to neonate.

C D Wear1, C V Towers1, M S Brown1, B Weitz1, S Porter1, L Wolfe1.   

Abstract

OBJECTIVE: To evaluate maternal and neonatal cord blood levels at delivery in patients receiving 900 mg of clindamycin intravenous (IV) every 8 h. STUDY
DESIGN: Prospective study consented every mother that entered labor with a positive group B streptococcal culture, a high-risk penicillin allergy, and sensitivity to clindamycin and erythromycin. Maternal and cord blood clindamycin levels were obtained at delivery. Time from last dose completion to delivery, number of doses administered and body mass index (BMI) were assessed.
RESULTS: Twenty-three patients were consented. All maternal clindamycin values were therapeutic and 22 (96%) of the 23 cord blood samples were therapeutic. The mean maternal level was of 4.46 μg ml-1 (range of 0.7 to 8.4 μg ml-1). The mean cord blood level was 3.35 μg ml-1 (range of <0.5 to 6.4 μg ml-1).
CONCLUSION: These data show that the current dosing recommendation of 900 mg of clindamycin IV every 8 h produces therapeutic maternal and cord blood levels.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27490192     DOI: 10.1038/jp.2016.122

Source DB:  PubMed          Journal:  J Perinatol        ISSN: 0743-8346            Impact factor:   2.521


  6 in total

1.  Prevention of perinatal group B streptococcal disease--revised guidelines from CDC, 2010.

Authors:  Jennifer R Verani; Lesley McGee; Stephanie J Schrag
Journal:  MMWR Recomm Rep       Date:  2010-11-19

Review 2.  ACOG Committee Opinion No. 485: Prevention of early-onset group B streptococcal disease in newborns.

Authors: 
Journal:  Obstet Gynecol       Date:  2011-04       Impact factor: 7.661

3.  Placental transfer of clindamycin and gentamicin in term pregnancy.

Authors:  A J Weinstein; R S Gibbs; M Gallagher
Journal:  Am J Obstet Gynecol       Date:  1976-04-01       Impact factor: 8.661

4.  Transplacental passage of erythromycin and clindamycin.

Authors:  A Philipson; L D Sabath; D Charles
Journal:  N Engl J Med       Date:  1973-06-07       Impact factor: 91.245

5.  Pharmacokinetics of clindamycin in pregnant women in the peripartum period.

Authors:  Anouk E Muller; Johan W Mouton; Paul M Oostvogel; P Joep Dörr; Rob A Voskuyl; Joost DeJongh; Eric A P Steegers; Meindert Danhof
Journal:  Antimicrob Agents Chemother       Date:  2010-02-22       Impact factor: 5.191

6.  Antibiotic concentration in maternal blood, cord blood, and placental membranes in chorioamnionitis.

Authors:  L C Gilstrap; R E Bawdon; J Burris
Journal:  Obstet Gynecol       Date:  1988-07       Impact factor: 7.661

  6 in total
  1 in total

Review 1.  Ways to Improve Insights into Clindamycin Pharmacology and Pharmacokinetics Tailored to Practice.

Authors:  Laura Armengol Álvarez; Greet Van de Sijpe; Stefanie Desmet; Willem-Jan Metsemakers; Isabel Spriet; Karel Allegaert; Jef Rozenski
Journal:  Antibiotics (Basel)       Date:  2022-05-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.